First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma (Q81071045)
Jump to navigation
Jump to search
scientific article published on 11 April 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma |
scientific article published on 11 April 2008 |
Statements
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma (English)
C Szczylik
B Melichar
P Koralewski
S Bracarda
C Chevreau
M Filipek
R Delva
E Sevin
S Négrier
J McKendrick
A Santoro
P Pisa